RT Journal Article SR Electronic T1 Progress in Drug Therapy for Multiple Myeloma JF Chinese Journal of Clinical Oncology JO Cancer Biol Med FD China Anti-Cancer Association SP 251 OP 257 DO 10.1007/s11805-008-0251-8 VO 5 IS 4 A1 Shun’e Yang A1 Bing Zhao YR 2008 UL http://www.cancerbiomed.org/content/5/4/251.abstract AB Multiple myeloma remains incurable with conventional treatments. However, new active drugs, including the immunomodulatory agents, thalidomide and lenalidomide, and the proteasome inhibitors bortezomib and NPI-0052, and other targeted therapies, have shown promising anti-myeloma activity. These agents represent a new generation of treatments for multiple myeloma that affect both specific intracellular signaling pathways and the tumor microenvironment. This review therefore focuses on the extensive clinical data available from studies of these drugs in the treatment of newly diagnosed, refractory and relapsed multiple myeloma.